This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer.
In this video, Guru Sonpavde, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, reviews three new studies involving rare genitourinary cancers: a phase II study of pazopanib in von Hippel-Lindau disease (abstract 4516), a comprehensive genomic profiling of advanced papillary renal cell carcinoma (abstract 4517), and a multiregion sequencing of penile cancer that revealed actionable mutations (abstract 4519).
Sonpavde was the discussant during a poster discussion session on the identification and targeting of genetic drivers of rare genitourinary cancers, which featured these three studies, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.
Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship
The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.